Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Purpose: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor with few treatment options. We designed a phase II randomized trial to determine the activity and tolerability of single -agent cediranib or sunitinib in patients with advanced metastatic ASPS.Patients and Methods: Patients 16 years of age and older were randomized to receive cediranib (30 mg) or sunitinib (37.5 mg) in 28-day cycles. Patients could cross over to the other treatment arm at disease progression. The primary endpoint was to mea-sure the objective response rate (ORR) for each agent. Median progression-free survival (mPFS) for the two arms was also determined.Results: Twenty-nine of 34 enrolled patients were evaluable for response. One patient on each of the initial two treatment arms hada partial response (ORR: 6.7% and 7.1% for cediranib and sunitinib, respectively). Twenty-four patients had a best response of stable disease (86.7% and 78.6% for cediranib and sunitinib, respectively). There were no significant differences in mPFS for the two treatment arms. Clinical benefit (i.e., objective response or stable disease for a minimum of four or six cycles of therapy) on the first-line tyrosine kinase inhibitor (TKI) therapy did not predict benefit on the second-line TKI. Both drugs were well tolerated. As of August 2021, 1 patient (unevaluable for ORR) remains on study.Conclusions: The study did not meet its endpoints for ORR. Although both TKIs provided clinical benefit, the outcomes may have been attenuated in patients who had progressed <= 6 months before enrollment, potentially accounting for the low response rates. See related commentary by Wilky and Maleddu, p. 1163